Suvi T. M. Orr - Concepedia

Author

Suvi T. M. Orr

Also Known As

Orr, Suvi T. M., S Orr, S. T. M. Orr, Suvi Orr, Suvi T. M Orr, Suvi T. M. Orr, Suvi T.M. Orr, Suvi T.M. Orr (nee Simila)

Publications

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)WuXi AppTec (China)Foton Motors (China)

About

Suvi T. M. Orr is an author at Pfizer (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	566
2	Biochemistry	8	8	419
3	Natural Sciences	7	7	389
4	Cell Biology	2	2	131
5	Health Sciences	1	1	42

Suvi T. M. Orr

Publications

678

Citations

H-Index

Page 1

	Year	Citations
Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR Simon Planken, Douglas C. Behenna, Sajiv K. Nair, Journal of Medicinal Chemistry Molecular BiologyWild-type EgfrChemical BiologyTumor BiologyMolecular Pharmacology	2017	89
Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2) Kentaro Futatsugi, Daniel W. Kung, Suvi T. M. Orr, Journal of Medicinal Chemistry Combinatorial ChemistryLipid AnalysisMedicinal ChemistryBioorganic ChemistryLipid Synthesis	2015	80
Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. L H Patterson, S. R. McKeown, Tracy Robson, PubMed Molecular PharmacologyCyp3a MrnaChemoprevention StrategyBiochemistryOncogenic Agent	1999	77
Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate Samit K. Bhattacharya, Kim Andrews, Ramsay E. Beveridge, ACS Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryBiochemistryG Protein-coupled ReceptorMedicine	2014	67
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2<i>H</i>)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases Roger B. Ruggeri, Leonard Buckbinder, Scott W. Bagley, Journal of Medicinal Chemistry Lipid PeroxidationCardiovascular PharmacologyPharmacotherapyThyroid PeroxidaseCardiovascular Diseases	2015	57
Identification of Tetrahydropyrido[4,3-<i>d</i>]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists David W. Piotrowski, Kentaro Futatsugi, Joseph S. Warmus, ACS Medicinal Chemistry Letters Pharmaceutical ScienceImmunologyPharmacotherapyChemical BiologyAcceptable Potency	2012	47
Discovery of an <i>in Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment Mark Ammirati, Scott W. Bagley, Samit K. Bhattacharya, ACS Medicinal Chemistry Letters Map4k4-based Antidiabetic TreatmentPharmaceutical SciencePharmaceutical ChemistryInsulin SignalingTranslational Medicine	2015	42
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195) Hengmiao Cheng, Suvi T. M. Orr, Simon Bailey, Journal of Medicinal Chemistry	2020	39
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety Cynthia L. Palmer, Britton Boras, Bernadette Pascual, Cancer Cell	2025	35
Optimization of triazole-based TGR5 agonists towards orally available agents Kentaro Futatsugi, Kevin B. Bahnck, Martin Brenner, MedChemComm Medicinal ChemistryPharmaceutical ScienceScreening StrategyPreclinical Drug EvaluationMedicine	2012	31

Page 1